PYC Share PerformanceMore
|52 week high||4.3000 07/09/16|
|52 week low||0.9340 17/07/17|
|52 week change||-2.0000 (-61.54%)|
|4 week volume||4,553,724 30/06/17|
Latest News« previous» nextMore
06/06/2017 - 07:00 RNS
RNS Number: 1956H Physiomics PLC 06 June 2017 Physiomics Plc ("Physiomics" or "the Company") Physiomics to attend PAGE 2017 Oxford, UK, 6 th June 2017: Physiomics is pleased to announce that it will attend the Population Approach Group Europe (PAGE) Annual Conference taking place in Budapest, Hungary 7-9 June. PAGE is Europe's premier conference ...
24/05/2017 - 07:00 RNS
RNS Number: 0270G Physiomics PLC 24 May 2017 Physiomics plc ("Physiomics") or ("the Company") Update: two further extension projects to advance oncology candidate with global pharma company Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been contracted for two further extensions to a Virt...
05/05/2017 - 07:00 RNS
RNS Number: 2352E Physiomics PLC 05 May 2017 Physiomics Plc ("Physiomics" or "the Company") Physiomics to Present at BioTrinity 2017 Oxford, UK, 5 th May 2017: Physiomics is pleased to announce that it will attend BioTrinity 2017. BioTrinity is one of Europe's leading Biopartnering and Investment Conferences, to be held on 8-10 May at the Novotel London W...
24/03/2017 - 15:05 StockMarketWire
Physiomics has reported an operating loss of 263,509 for the six month period ended 31 December, compared to a restated lo...
24/03/2017 - 12:15 RNS
RNS Number: 4688A Physiomics PLC 24 March 2017 Physiomics Plc ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2016 Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2...
11/01/2017 - 08:51 StockMarketWire
Physiomics anticipates that in H1 of its current financial year revenues will be broadly in line with the comparable period...
11/01/2017 - 08:00 RNS
RNS Number: 8389T Physiomics PLC 11 January 2017 Physiomics plc ("Physiomics") or ("the Company") Company Update Physiomics plc (AIM: PYC) is pleased to announce that it is making good progress towards the strategic objectives announced in its most recent full year results (RNS 27 th October 2016 and subsequent printed annual report circulated to shareho...
06/01/2017 - 08:12 StockMarketWire
Physiomics confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Stu...
|Dividend yield||0 %|
Equity Research (PYC)
The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients...
The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives...
Following the decision not to proceed with the acquisition of oncology therapeutics Company BioMoti, Physiomics is now 100% focused on growing the revenues and creating a path to profitability in the...
Latest discussion posts More
“Don't buy, ok....”▼
“interesting news folks.top up if you can.gla”▼
Codes & Symbols
|Symbols||PYC, LSE:PYC, PYC.L, PYC:LN, LON:PYC, XLON:PYC|